205 related articles for article (PubMed ID: 28872228)
1. Pembrolizumab-induced hepatitis: diagnosis and treatment.
Forschner A; Schraml C; Pierchalla K; Weide B; Eigentler TK; Lauer UM; Garbe C
J Dtsch Dermatol Ges; 2017 Sep; 15(9):933-935. PubMed ID: 28872228
[No Abstract] [Full Text] [Related]
2. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
3. In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.
Med Lett Drugs Ther; 2018 Jan; 60(1537):e8. PubMed ID: 29294466
[No Abstract] [Full Text] [Related]
4. Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma.
Stuart L; Lambourne B; Turner P; Jones DEJ; Plummer R; Cresti N; Dyson JK
Hepatology; 2020 Jun; 71(6):2164-2166. PubMed ID: 31872447
[No Abstract] [Full Text] [Related]
5. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
[No Abstract] [Full Text] [Related]
6. Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.
Rickard F; Hyams C; Low AT
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29735504
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-Induced Extensive Panniculitis and Nevus Regression: Two Novel Cutaneous Manifestations of the Post-immunotherapy Granulomatous Reactions Spectrum.
Burillo-Martinez S; Morales-Raya C; Prieto-Barrios M; Rodriguez-Peralto JL; Ortiz-Romero PL
JAMA Dermatol; 2017 Jul; 153(7):721-722. PubMed ID: 28467548
[No Abstract] [Full Text] [Related]
8. Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
Algaeed M; Mukharesh L; Heinzelmann M; Kaminski HJ
Neurology; 2018 Oct; 91(14):e1365-e1367. PubMed ID: 30275130
[No Abstract] [Full Text] [Related]
9. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
[No Abstract] [Full Text] [Related]
10. Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma.
Cheshire SC; Board RE; Lewis AR; Gudur LD; Dobson MJ
Radiology; 2018 Nov; 289(2):564-567. PubMed ID: 30106351
[TBL] [Abstract][Full Text] [Related]
11. Vasculitic neuropathy induced by pembrolizumab.
Aya F; Ruiz-Esquide V; Viladot M; Font C; Prieto-González S; Prat A; Arance A
Ann Oncol; 2017 Feb; 28(2):433-434. PubMed ID: 27864214
[No Abstract] [Full Text] [Related]
12. An unknown reaction to pembrolizumab: giant cell arteritis.
Micaily I; Chernoff M
Ann Oncol; 2017 Oct; 28(10):2621-2622. PubMed ID: 28633343
[No Abstract] [Full Text] [Related]
13. Pembrolizumab in advanced head and neck cancer.
Brower V
Lancet Oncol; 2017 May; 18(5):e248. PubMed ID: 28366274
[No Abstract] [Full Text] [Related]
14. Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars.
McKenna MC; Molloy K; Crowther S; Feeney J; Gillis A; Connolly M; Kelleher F
J Oncol Pract; 2018 Mar; 14(3):200-201. PubMed ID: 29300520
[No Abstract] [Full Text] [Related]
15. New Indication for Cancer Drug Based on Biomarkers.
Aschenbrenner DS
Am J Nurs; 2017 Sep; 117(9):22. PubMed ID: 28837483
[No Abstract] [Full Text] [Related]
16. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer].
Yonenobu Y; Ishijima M; Toyooka K; Fujimura H
Rinsho Shinkeigaku; 2019 Feb; 59(2):105-108. PubMed ID: 30700688
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
Haddox CL; Shenoy N; Shah KK; Kao JC; Jain S; Halfdanarson TR; Wijdicks EF; Goetz MP
Ann Oncol; 2017 Mar; 28(3):673-675. PubMed ID: 27993808
[No Abstract] [Full Text] [Related]
18. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
19. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
[No Abstract] [Full Text] [Related]
20. Esophagitis in Non-Small Cell Lung Carcinoma Treatment Caused by Pembrolizumab.
Yoshida S; Miyamoto S; Naruse H; Ito J; Kinosita K; Kudo T; Hatanaka K; Yamamoto Y; Sakamoto N
Am J Gastroenterol; 2020 Jan; 115(1):13. PubMed ID: 31356230
[No Abstract] [Full Text] [Related]
[Next] [New Search]